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Abstract 
 
The aim of the present work was to shed light on the role played by the isoprenoid/cholesterol 
biosynthetic pathway in the modulation of emotional reactivity and memory consolidation in 
rodents through the inhibition of the key and rate-limiting enzyme 3-hydroxy 3-methylglutaryl 
Coenzyme A reductase (HMGR) both in vivo and in vitro with simvastatin.   
Three-month-old male Wistar rats treated for 21 days with simvastatin or vehicle were tested in the 
social interaction, elevated plus-maze, and inhibitory avoidance tasks; after behavioral testing, the 
amygdala, hippocampus, prefrontal cortex, dorsal and ventral striatum were dissected out for 
biochemical assays. In order to delve deeper into the molecular mechanisms underlying the 
observed effects,  primary rat hippocampal neurons were used.  
Our results show that HMGR inhibition by simvastatin induces anxiogenic-like effects in the social 
interaction but not in the elevated plus maze test, and improves memory consolidation in the 
inhibitory avoidance task. These effects are accompanied by imbalances in the activity of specific 
prenylated proteins, Rab3 and RhoA, involved in neurotransmitter release and synaptic plasticity, 
respectively. Taken together, the present findings indicate that the isoprenoid/cholesterol 
biosynthetic pathway is critically involved in the physiological modulation of both emotional and 
cognitive processes in rodents. 
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INTRODUCTION  
The isoprenoid/cholesterol biosynthetic pathway, also known as mevalonate (MVA) pathway, is 
one of the most notorious metabolic processes since it leads to the production of cholesterol and 
other non-sterol isoprenoids which are essential in the induction and the maintenance of several 
cellular processes. The key enzyme of this pathway is the 3-hydroxy-3-methylglutaryl coenzyme A 
reductase (HMGR) (Brown and Goldstein, 1980; Segatto et al, 2013). The role of MVA pathway is 
well established in the liver, where a major part of lipid metabolism takes place (Horton, 2002; 
Pallottini et al, 2007; Segatto et al, 2013). However this metabolic pathway is ubiquitously 
expressed in all eukaryotic cells, and recent studies sustain a pivotal role for MVA end-products in 
the brain. Although the CNS constitutes the 2% of the body weight, it contains about 25% of the 
total body cholesterol (Pfrieger, 2003; Segatto et al, 2013). The majority of cholesterol is present in 
myelin sheaths and in neuronal membranes, where this lipid fulfills structural and functional tasks. 
Given the crucial role of cholesterol in regulating different neuronal processes, eukaryotes have 
developed sophisticated homeostatic mechanisms to preserve cholesterol levels in an optimal range 
in each brain region (Segatto et al, 2013). Thus, alterations in this essential equilibrium could lead 
to pathological consequences in the CNS, such as Smith-Lemli-Opitz syndrome, Alzheimer’s  and 
Niemann-Pick type C diseases (Dietschy and Turley, 2004; Pfrieger, 2003; Segatto et al, 2011). 
Besides cholesterol, isoprenoid compounds carry out important roles in the CNS. Prenylation, the 
covalent binding of farnesyl pyrophosphate (FPP) or geranylgeranyl pyrophosphate (GGPP) 
moieties to proteins, is a crucial post-translational modification for the regulation of protein 
localization on cell membranes and, in turn, for key cellular processes. Isoprenoids are not only 
required for protein prenylation, but also constitute the side chain of Coenzyme Q (CoQ) (Matthews 
et al, 1998), whereas dolichols are involved in the N-linked glycosylation of proteins (Trapani et al, 
2011b). 
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The essential role of MVA end-products in the CNS physiology is also supported by growing pre-
clinical and clinical studies on the pleiotropic effects of statins in the brain. Statins are strong 
HMGR inhibitors widely prescribed in therapies against hypercholesterolemia and their benefits in 
preventing atherosclerosis and other cardiovascular diseases are incontrovertible. Recently, it has 
been reported that high dose statin treatment induces effects in emotional, learning and memory 
processes (Kilic et al, 2012; Douma et al, 2011; Baytan et al, 2008; While and Keen, 2010). 
However, the role of the MVA biosynthetic pathway in the modulation of emotional behavior and 
cognitive performance is still unclear because of the lack of systematic studies on the causal link 
between the activation of this metabolic pathway and behavioral and cognitive outcomes. As a 
consequence, the effects exerted by statins in the CNS still remain confusing and unconvincing. 
Moreover, no data about a low-dose statin treatment is available. A better understanding of these 
processes could be of great interest towards new pharmacological interventions for CNS disorders. 
Thus, the aim of the present work was to shed light on the role played by the MVA pathway in the 
modulation of emotional reactivity and memory consolidation in rodents, through  the inhibition  by 
simvastatin of HMGR both in vivo and in vitro.   
 
MATERIALS AND METHODS 
Animals 
Three-months-old male Wistar rats (Harlan Nossan, S. Pietro al Natisone, Italy) were housed in 
groups of two and maintained under controlled temperature (20 ± 1 °C), humidity (55 ± 10%) and 
illumination (12/12 h light cycle with lights on at 7.00 a.m.). Food and water were provided ad 
libitum. All procedures involving animal care or treatments were approved by the Italian Ministry 
of Health and performed in compliance with the guidelines of the US National Institutes of Health 
(NIH) and the Italian Ministry of Health (n° 231/2012-B, according to D.L. 116/92), the 
Declaration of Helsinki, the Guide for the Care and Use of Mammals in Neuroscience and 
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Behavioral Research (National Research Council 2004) and the  Directive 2010/63/EU of the 
European Parliament and of the Council of 22 September 2010 on the protection of animals used for 
scientific purposes.  
Drug Treatment 
Simvastatin (Sigma Aldrich, Milan, Italy) was dissolved in a vehicle containing dimethyl sulfoxide 
- 250 μl/kg body weight of 10% DMSO in sterile H2O (v/v) - and the dose of 1.5 mg/kg  was daily 
administered by intraperitoneal injections for 3 weeks. Control animals were treated with vehicle 
only. Immediately after testing, rats were deeply anesthetized using Urethane (1.2 mg/kg) and 
plasma obtained from blood collected into EDTA (1 mg/ml blood). Subsequently, rats were 
decapitated and their brains quickly removed. Brain regions of interest (amygdala, hippocampus, 
prefrontal cortex, dorsal and ventral striatum) were collected and frozen in liquid nitrogen for 
subsequent biochemical analyses.  
Plasma cholesterol analysis 
Plasma cholesterol content was estimated by the colorimetric CHOD-POD kit in accordance to the 
manufacturer’s instructions (Assel, Rome, Italy).  
Plasma triglycerides analysis 
The amount of plasma triglycerides was assessed by using the Triglyceride Quantification Kit in 
accordance to the manufacturer’s instructions (BioVision, Mountain View, CA).  
Behavioral tests 
The behavioral experiments were performed the day following the last administration of either 
simvastatin or vehicle. Different groups of rats were used for each behavioral test. 
Social interaction test 
The social interaction test was performed under dim light conditions in a Plexiglas arena (45 x 45 x 
60 cm) with approximately 2 cm of wood shavings covering the floor.  
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The test consisted in placing two similarly treated animals into the test cage for 10 min, with new 
sawdust as bedding. The animals in a pair did not differ more than 10 g in body weight; 
furthermore, they were housed in different cages and that therefore had no previous common social 
experience from the arrival in our Facility till the day of testing (File, 1980; Trezza et al, 2008).  
The behavior of the animals was recorded on DVD for subsequent appropriate behavioral analysis 
carried out by the same observer, who was unaware of animal treatment, using the Observer 3.0 
software (Noldus Information Technology B.V., Wageningen, The Netherlands).  
The total time spent in active social interaction was obtained as the sum of the time spent in the 
following behavioral elements scored per 10 min: 
– Play-related behaviors: 1. total time spent in pouncing (i.e., when one animal attempts to nose or 
rub the nape of the neck of its  play partner) which is an index of play solicitation; 2. total time 
spent in pinning (i.e., the most common terminal component of a play bout, in which one animal 
stands over a supine partner), which is the consummatory measure of play (Panksepp et al, 1984; 
Trezza et al, 2010). 
– Social behaviors unrelated to play: total time spent in social exploration (sniffing any part of the 
body of the test partner, including the anogenital area; social grooming; following/chasing). 
Elevated plus-maze 
The elevated plus-maze test was performed as previously described (Pellow and File, 1986; Trezza 
et al, 2009). Briefly, the rats were individually placed on the central platform of the maze, facing a 
closed arm, and allowed to freely explore the maze for 5 min.  
The 5 min test period was recorded on DVD for subsequent appropriate behavioral analysis carried 
out by the same observer, unaware of animal treatment, using the Observer 3.0 software (Noldus 
Information Technology B.V., Wageningen, The Netherlands).  
The following parameters were analyzed: 
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a. % time spent on the open arms (% TO): (seconds spent on the open arms of the maze/300) × 
100; 
b. % open arm entries (% OE): (the number of entries into the open arms of the maze/ number 
of entries into open + centre + closed arms) × 100; 
c. number of total arm entries (open + closed arm entries). 
Inhibitory Avoidance 
The inhibitory-avoidance apparatus (Ugo Basile, Comerio, Italy) consisted of a Plexiglas cage with 
tilting floor, divided by a sliding door into two compartments (22×22×25 cm each). One of the 
compartments had white walls and was brightly illuminated by a 10-W bulb. The other 
compartment had black walls and was not illuminated. The tilting floor consisted of bars of stainless 
steel connected to a source of scrambled shock. The procedure consisted of two sessions, 
acquisition and retention, that took place on 2 subsequent days (Mereu et al, 2003; Campolongo et 
al, 2007). For details see Supplementary Materials and Methods. 
Lipid extraction 
Lipid extraction from brain regions (amygdala, hippocampus, prefrontal cortex, dorsal striatum and 
ventral striatum) was assessed by following the previously described protocol (Trapani et al, 
2011a).  
HPLC-UV analysis of isoprenoids 
Cholesterol, Coenzyme Q9 (CoQ9), Coenzyme Q10 (CoQ10) and dolichols were analyzed 
according to the previously described protocol (Tang et al, 2001) with modifications. For details see 
Supplementary Materials and Methods.  
Lysate, cytosol and membrane preparation from brain tissue 
Lysate and membrane from brain tissue were prepared slightly modifying our previously used 
protocol (Segatto et al, 2011). For details, see Supplementary Materials and Methods.  
Synaptic vesicle preparation 
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Synaptic vesicles were prepared following the protocol described by Huttner et al. (1983) with 
modifications. Rat brain regions (amygdala, hippocampus, prefrontal cortex, dorsal striatum and 
ventral striatum) were homogenized in 10 volumes of ice cold HEPES-buffered sucrose (4 mM 
HEPES, 0.32 M sucrose, 0.001 M PMSF, pH 7.4) with 10 strokes in a glass-Teflon homogenizer. 
Homogenates were centrifuged at 1,000 g to remove nuclei, intact cells and cell debris (P1 fraction). 
The supernatant (S1) was spun at 10,000 g for 15 min to yield the crude synaptosomal pellet (P2). 
The supernatant (S2) was collected and subsequently centrifuged at 100,000 g for 15 min to 
produce the cytosolic fraction (S2’). The P2 fraction was then resuspended in 10 volumes of 
HEPES-buffered sucrose and respun at 10,000 g for 15 min to obtain the washed crude 
synaptosomal fraction (P2’). The resulting pellet was lysed by hypoosmotic shock in 9 volumes of 
ice cold distilled water plus 0.001 M PMSF and three strokes of a glass-Teflon homogenizer. 4 mM 
HEPES (pH 7.4) was rapidly added to the lysate which was mixed continuously in a cold room for 
30 min to guarantee the total lysis of the sample. The lysate was subsequently centrifuged at 25,000 
g for 20 min and the supernatant (S3) was collected and spun at 165,000 g for 2 hours. The pellet of 
synaptic vesicles was finally solubilized in a sample buffer (0.125M Tris–HCl -pH 6.8- containing 
10% SDS, 0.001 M PMSF) and transferred into 1.5 ml Eppendorf tubes. Protein determination was 
assessed by the method of Lowry et al. (Lowry et al, 1951). The synaptic vesicle samples were 
boiled for 3 min before loading for Western blotting method. In order to obtain an adequate amount 
of synaptic vesicles, each sample was made up from six brain regions pulled together from six 
different animals. The protein detection of synaptophysin (synaptic vesicle marker) and α-tubulin 
(cytosolic marker) verified and confirmed a high degree of purity of the synaptic vesicles (Figure 
S1). 
Rab3 “in vitro” degradation assay 
Rab3 degradation assay was performed according to the protocol used by Pallottini et al., (Pallottini 
et al, 2004) with modifications. For details see Supplementary Materials and Methods.  
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Hippocampal neuron primary cultures and drug treatment 
Primary hippocampal neurons were isolated and cultured according to the previously described 
protocol (Oh et al, 2006). For details see Supplementary Materials and Methods. 
Western blotting analysis 
Western blot method was performed slightly modifying the protocol described by Trapani et al. 
(Trapani et al, 2011a) by using the following antibodies: LDLr ab30532 (Abcam); SREBP-2 
ab28482 (Abcam); NeuN A60 (Chemicon); GFAP 134B1 (Synaptic Systems); Rab3 G-1, CREB, p-
CREB, H-Ras M90, RhoA 26C4, Akt1 B-1, RhoGDI A-20, RabGDI (V-20)-R, synaptophysin H-
93, caveolin N-20 (Santa Cruz Biotechnology); p-Akt 193H12 (Cell Signaling). For details see the 
Supplementary Materials and Methods. 
Immunohistochemistry 
Immunohistochemical staining of p-CREB and PSD-95 was performed on sagittal brain sections of 
simvastatin- and vehicle-treated animals according to the previously used protocols (Moreno et al, 
1995; Fanelli et al, 2013). For details see Supplementary Materials and Methods. 
Statistical analysis 
Data obtained from behavioral tests are expressed as means ± SEM (standard error of the mean); 
data derived from the analysis of biochemical results are expressed as means ± SD (standard 
deviation). Data were analyzed with unpaired Student’s t test or with one-way analysis of variance 
(ANOVA) followed by Dunnett post-test. Values of P < 0.05 were considered to indicate a 
significant difference. Statistical analysis was performed using GRAPHPAD INSTAT3 (GraphPad, 
La Jolla, CA, USA) for Windows. 
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RESULTS 
Systemic effects of HMGR inhibition on lipid metabolism 
The inhibition of HMGR, and in turn the reduction in MVA end-products formation, leads to a 
homeostatic response which determines the increase of the Low Density Lipoprotein (LDL) 
receptor family members through the enhancement of their transcription and translocation onto cell 
membranes, subsequently reducing the amount of plasma lipids (Jones et al, 1998). Thus, the 
efficacy of the pharmacological treatment was checked by estimating plasma cholesterol and 
triglycerides. As shown in Table S1, both cholesterol (t34 = 3,606, p = 0,001) and triglycerides (t34 = 
4,562, p > 0,0001) significantly decreased after simvastatin treatment (18% and 32%, respectively). 
Nevertheless, similar body weight of simvastatin- and vehicle-treated rats was observed, indicating 
that HMGR inhibition failed to induce changes in the basal metabolism of the animals (data not 
shown). 
Effects of HMGR inhibition on emotional reactivity and cognitive performance  
To evaluate the potential role of MVA pathway inhibition by simvastatin in the modulation of 
emotional reactivity, rats were tested in the social interaction and elevated plus maze tests, two 
validated animal methods to evaluate anxiety in rodents.  
Chronic simvastatin treatment decreased the total time spent in active social interaction compared 
with vehicle-treated rats (t18 = 4,123, p < 0,001; Figure 1a), expressed as the sum of the time spent 
in play-related behaviors (t18 = 3,386, p = 0,003; figure not shown) and in social behaviors unrelated 
to play (t18 = 2,390, p = 0,028; figure not shown). In contrast, the percentage of time spent in the 
open arms (t19 = -1,349, p = 0,193; Figure 1b), the percentage of open entries (t19 = -1,062, p = 
0,302; Figure 1c) and the total arm entries (t19 = 1,768, p = 0,093; Figure 1d) evaluated in the 
elevated plus-maze test were  unaffected by the pharmacological inhibition of  HMGR. 
To investigate whether MVA pathway has a role in the modulation of memory consolidation, rats 
were tested in the inhibitory avoidance task. Chronic simvastatin treatment had no effect on the 
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approach latencies during the acquisition trial (t17 = -0,620, p = 0,544; Figure 1e); however, it 
caused a statistically significant improvement in 24-hours retention performance (t17 = -2,245, p = 
0,038; Figure 1f). This effects was not secondary to drug-induced hypersensivity to the electrical 
shock delivered during the acquisition trial, since simvastatin- and vehicle-treated rats did not  
differ in the response to the aversive stimulus during the acquisition trial (t17 = -0,204, p = 0,841; 
Figure 1g). 
Simvastatin efficacy and tolerance in the CNS 
Evidence for the drug efficacy in the CNS were given by checking the levels of the active nuclear 
fraction of the transcription factor SREBP-2 (nSREBP-2) and the subsequent increase in LDL 
receptor (LDLr), that are induced by a compensative response due to intracellular cholesterol 
decrease (Brown and Goldstein, 1997; Trapani et al, 2011a). The biochemical analysis were mainly 
carried out on amygdala, hippocampus, prefrontal cortex, dorsal striatum and ventral striatum, 
whose interplay is deeply involved in the modulation of anxiety, memory and learning (Mathew et 
al, 2001; LaBar and Cabeza, 2006). Our results showed that HMGR inhibition by chronic 
simvastatin treatment induced a classical feedback response, which led to a strong increase of the 
active nSREBP-2 in all the brain regions analyzed (amygdala: t10 = 2,139, p = 0,0291; 
hippocampus: t10 = 2,434, p = 0,0176; prefrontal cortex: t10 = 2,590, p = 0,0135; dorsal striatum:  t10 
= 2,045, p = 0,034; ventral striatum: t10 = 2,637, p = 0,0124; Figure 2a). HMGR inhibition was also 
supported by the subsequent and the contributory increase in LDLr expression (amygdala: t10 = 
2,263, p = 0,0236; hippocampus: t10 = 2,057, p = 0,0334; prefrontal cortex: t10 = 1,933, p = 0,0410; 
dorsal striatum: t10 = 1,909, p = 0,0427; ventral striatum: t10 = 3,969, p = 0,0013; Figure 2b). 
Moreover, the direct proof of the pharmacological inhibition was also given by assessing HMGR 
activity (amygdala: t8 = 7,694, p < 0,0001; hippocampus: t8 = 12,66, p < 0,0001; prefrontal cortex: t8 
= 7,259, p < 0,0001; dorsal striatum: t8 = 4,934, p = 0,0011; ventral striatum: t8 = 5,092, p = 0,0009; 
Figure S2a) which was reduced in all the analyzed brain areas. 
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Once simvastatin efficacy was ascertained, we focused on the potential toxic effects exerted by 
HMGR inhibition on different brain areas. Protein levels of the neuronal marker NeuN (amygdala: 
t10 = 1,627, p = 0,0674; hippocampus: t10 = 0,9974, p = 0,1710; prefrontal cortex: t10 = 1,271, p = 
0,1162; dorsal striatum: t10 = 5,005, p = 0,3138; ventral striatum: t10 = 0,8166, p = 0,2166; Figure 
2c) and of the astrocyte marker GFAP (amygdala: t10 = 0,5949, p = 0,4769; hippocampus: t10 = 
1,614, p = 0,0688; prefrontal cortex: t10 = 1,358, p = 0,1022; dorsal striatum: t10 = 0,8068, p = 
0,2193; ventral striatum: t10 = 0,7905, p = 0,2238; Figure 2d) were unchanged in the examined brain 
areas. The analysis of cleaved caspase-3 also showed that the protein levels of this executive 
caspase were unaffected by simvastatin treatment (amygdala: t10 = 0,5627, p = 0,2930; 
hippocampus: t10 = 0,06597, p = 0,4744; prefrontal cortex: t10 = 0,8944, p = 0,1961; dorsal striatum: 
t10 = 0,7460, p = 0,2364; ventral striatum: t10 = 0,06921, p = 0,4731; Figure S2b). 
Effect of simvastatin on cholesterol, dolichols and CoQs 
A prospective perturbation in MVA pathway end-products induced by HMGR inhibition could be at 
the root of the behavioral and cognitive effects observed in vivo.  
Thus, lipid estimation was performed in order to evaluate the effect of simvastatin on the main 
sterol and non-sterol compounds. As observable in Table 1, tissue cholesterol (amygdala: t7 = 
0,2031, p = 0,8448; hippocampus: t8 = 0,3502, p = 0,7352; prefrontal cortex: t8 = 0,4874, p = 
0,6391; dorsal striatum: t7 = 1,556, p = 0,1636; ventral striatum: t6 = 0,5193, p = 0,6221), coenzyme 
Q9 (CoQ9) (amygdala: t6 = 0,1524, p = 0,8838; hippocampus: t8 = 0,04377, p = 0,9662; prefrontal 
cortex: t8 = 1,211, p = 0,2605; dorsal striatum: t8 = 1,623, p = 0,1433; ventral striatum: t5 = 0,2318, p 
= 0,8259), coenzyme Q10 (CoQ10) (amygdala: t6 = 0,06480, p = 0,9504; hippocampus: t8 = 1,301, p 
= 0,2294; prefrontal cortex: t8 = 1,294, p = 0,2319; dorsal striatum: t8 = 1,440, p = 0,1879; ventral 
striatum: t5 = 0,2467, p = 0,8149), and dolichol (amygdala: t8 = 1,805, p = 0,1087; hippocampus: t8 = 
0,007556, p = 0,9942; prefrontal cortex: t8 = 0,9631, p = 0,3637; dorsal striatum: t8 = 0,2134, p = 
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0,8363; ventral striatum: t6 = 0,8525, p = 0,4266) were not affected by HMGR inhibition among the 
brain regions analyzed. 
Prenylated protein involved in synaptic vesicle release: Rab3 determination 
Simvastatin treatment could also induce a down-regulation in the activity of small GTPases by 
affecting their prenylation. For the pivotal role in neurotransmitter release, Rab3 protein localization 
was analyzed. Rab3 fraction associated with the synaptic vesicle membranes was strongly reduced 
in the hippocampus (t2 = 3,675, p = 0,0334; Figure 3a) and the prefrontal cortex (t2 = 7,178, p = 
0,0094; Figure 3a) after chronic simvastatin treatment, while no differences in the protein 
localization were observable in amygdala (t2 = 1,028, p = 0,4120; Figure 3a), dorsal striatum (t2 = 
1,592, p = 0,1262; Figure 3a) and ventral striatum (t2 = 0,3310, p = 0,3860; Figure 3a). It is well 
accepted that membrane versus cytoplasm localization of Rab3, and other prenylated small 
GTPases in general, mirrors the prenylation status and, as a consequence, the activity of the protein 
of interest (Seasholtz et al, 1999; Homma et al, 2008). Thus the amount of Rab3 active fraction was 
expressed as the membrane:cytosol ratio. To further assess Rab prenylation, co-
immunoprecipitation experiments between RabGDI and Rab3 were performed on cytosolic 
fractions. The level of prenylated Rab3 is strongly reduced in the hippocampus (t4 = 13,15, p = 
0,0002, Figure S3a) and the prefrontal cortex (t4 = 6,759, p = 0,0025, Figure S3b) of simvastatin-
treated rats. Moreover, the total amount of RabGDI both in the hippocampus (t6 = 1,422, p = 
0,2048, Figure S3c) and the prefrontal cortex (t6 = 0,8552, p = 0,4253, Figure S3d) did not change 
between the two experimental groups. The lack of the concurrent accumulation of unprenylated 
Rab3 in the cytosolic fraction (generally a typical phenomenon observed after statin administration) 
is in line with the results obtained by other research groups, who demonstrated that, under specific 
conditions, some prenylated proteins could have a shorter half-life compared with the membrane-
bound forms (Haklai et al, 1998; Indolfi et al, 2002). To test this hypothesis, an “in vitro” 
degradation assay of Rab3 was performed. The results show that Rab3 was more susceptible to 
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degradational events in the hippocampus and the prefrontal cortex, while no differences were 
detectable between the two experimental groups in the other brain regions (Figure 3b). 
Prenylated proteins involved in long-term potentiation: Ras and RhoA determination 
The enhanced memory consolidation in a 24h inhibitory avoidance task could correlate with 
changes in long-term potentiation (LTP). Thus, prenylated proteins such as Ras and RhoA, involved 
in the modulation of this form of synaptic plasticity (Mazzucchelli and Brambilla, 2000; Rex et al, 
2009) were evaluated. HMGR inhibition did not induce any statistically significant modification in 
Ras translocation (amygdala: t10 = 0,2375, p = 0,4085; hippocampus: t10 = 0,2929, p = 0,3881; 
prefrontal cortex: t10 = 0,2798, p = 0,3927; dorsal striatum: t10 = 0,01021, p = 0,4960; ventral 
striatum: t10 = 0,1791, p = 0,4307; Figure 4a), whereas it strongly reduced the active membrane-
bound form of RhoA in the amygdala (t10 = 2,701, p = 0,0111; Figure 4b) and the hippocampus (t10 
= 2,601, p = 0,0132; Figure 4b), with the contributory build-up of the protein in the cytosol. On the 
contrary, no differences were observable in the prefrontal cortex (t10 = 0,2867, p = 0,3901; Figure 
4b), the dorsal striatum (t10 = 1,442, p = 0,0899; Figure 4b) and the ventral striatum (t10 = 0,2531, p 
= 0,4026; Figure 4b). As for Rab3, co-immunoprecipitation experiments highlighted a reduction in 
RhoA/RhoGDI complexes in both the amygdala (t4 = 6,188, p = 0,0035, Figure S4a) and the 
hippocampus (t4 = 6,636, p = 0,0027, Figure S4b), without showing any change in RhoGDI protein 
content (amygdala: t6 = 1,493, p = 0,1860, Figure S4c; hippocampus: t6 = 0,5134, p = 0,6260, Figure 
S4d). In addition, the reduction in RhoA translocation to the membrane was accompanied by a 
marked and significant increase in Akt activation state in both the amygdala (t10 = 2,726, p = 
0,0107; Figure 4c) and the hippocampus (t10 = 2,724, p = 0,0107; Figure 4c), whereas no differences 
are detectable in the prefrontal cortex (t10 = 1,365, p = 0,1010; Figure 4c), the dorsal striatum (t10 = 
0,3652, p = 0,3613; Figure 4c) and the ventral striatum (t10 = 0,1979, p = 0,4236; Figure 4c). Similar 
results were also obtained from cell cultures. In primary rat hippocampal neurons, simvastatin 
treatment reproduced the reduction in RhoA active fraction observed in vivo, as demonstrated from 
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the decrease in the membrane:cytosol ratio (F(6, 21) = 4,016, p = 0,0078). The supplementation of 
the medium with either MVA (the direct product of HMGR) or geranylgeraniol (GG, one of the 
MVA pathway products and the substrate for RhoA prenylation) completely reversed the effect of 
the pharmacological inhibition of HMGR. On the other hand, the administration of MVA, GG and 
Rho kinase (ROCK) inhibitor hydroxyfasudil (HF) alone did not cause any effect in the protein 
translocation as expected (figure 5a). The estimation of Akt protein levels in primary neuronal 
culture strongly suggests that Akt phosphorylation was dependent on RhoA inhibition by 
simvastatin, as the co-administration of MVA and GG completely restored the basal levels of Akt 
activation state (F(6, 21) = 37,02, p < 0,0001). HF-mediated inhibition of ROCK, the main 
downstream effector of RhoA, further support this hypothesis by mimicking the effect of 
simvastatin through the induction of Akt phosphorylation (Figure 5b). Moreover, Akt activation 
induced a significant increase in the phosphorylation of the transcription factor CREB (F(6, 21) = 
4,849, p = 0,003; Figure 5c). 
Immunohistochemical analyses  
Morphological analysis of brains from either simvastatin- or vehicle-treated rats revealed good 
preservation of structures and overall normal cytoarchitecture.  Immunohistochemical localization 
of p-CREB showed wide neuronal distribution in the hippocampal formation of both treated and 
control groups. Immunostaining was mainly seen in the nucleus of pyramidal cells in CA1-CA3 
fields and of granule cells in DG. Also, mossy cells in the hylus were especially immunoreactive. 
Consistent with Western blot results obtained from primary hippocampal neuron cultures, 
remarkably higher immunostaining intensity throughout the hippocampus was detected in 
simvastatin-treated brains, as compared to their untreated counterparts (Figure 6a). PSD-95 also 
immunolocalized to pyramidal cell layer of CA1-CA3, to granule neurons of DG, and to hylar 
mossy neurons. However, at difference with p-CREB immunohistochemistry, the staining intensity 
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was comparable between the two experimental conditions, not being affected by simvastatin 
treatment (Figure 6b). 
 
 
DISCUSSION 
The present study was performed to provide a deeper understanding of CNS functional 
consequences following the pharmacological inhibition of the isoprenoid/cholesterol biosynthetic 
pathway in rodents. To this aim HMGR, the key and rate-limiting enzyme of this pathway, was 
inhibited in rats by chronic treatment with simvastatin, a powerful HMGR inhibitor which is able to 
cross the blood brain barrier because of its lipophilic properties (Saheki et al, 1994). To analyze the 
biological role of MVA pathway on rat emotionality, we performed two of the  most popular animal 
tests of anxiety currently used: the social interaction and the elevated plus maze tests (File and 
Hyde, 1978; File, 1980; Pellow et al, 1985; Pellow et al, 1986). Chronic simvastatin treatment at a 
low dose induced a significant decrease in the total time spent in active social investigation in the 
social interaction test, whereas no significant differences were observed in the elevated plus maze 
test. Although both the elevated plus maze and the social interaction tests are two validated animal 
models to measure anxiety-like behaviors in rodents (File, 1980; File and Seth, 2003; Pinheiro et al, 
2007; Pellow et al, 1986), it has been suggested that these tests evoke different states of anxiety in 
the laboratory animal (Gonzales et al, 1996; File, 1992) mediated by different neurobiological 
pathways (Cheeta et al, 2000; File et al, 2000; File et al, 2004) and thus they could have different 
sensitivity to simvastatin treatment. Specifically, it has been suggested that the elevated plus maze 
test mimics a state of generalized anxiety, since it produces an approach/avoidance conflict because 
the animal is exposed to a novel situation that supposedly creates a conflict between the motivation 
to explore the environment and an unconditioned fear of novelty (File et al, 2004), and this may be 
the underlying mechanism rendering the elevated plus maze test sensitive to anxiolytic-like drugs 
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(Handley and McBlane, 1993; Pinheiro et al, 2007). On the other hand, in the social interaction test, 
the variable is the time spent by pairs of male rats in active social interaction and one rat influences 
the behavior of the other; in fact, when pairs of male rats are placed in a situation in which neither 
one has established its territory, they engage in active social interaction (File et al, 1978). 
Nevertheless, the social interaction test is also sensitive to a number of environmental and 
physiological factors such as test conditions (light level and familiarity to the test arena) that can 
affect anxiety mimicking a state of anxiety most similar to that experienced in generalized anxiety 
disorder (File, 1980; File et al, 2003).  Furthermore, our results showed that the pharmacological 
modulation of MVA pathway end-products is also involved in the modulation of memory 
consolidation of aversive experiences; in particular, HMGR inhibition by simvastatin treatment led 
to a specific enhancement of the consolidation phase of the memory process, since the approach 
latency, measured during the first day of the test, did not differ between the two experimental 
groups. Our results also corroborate with existing and recently published data, showing that a higher 
dose of simvastatin (10 mg/kg) resulted in improved memory performance in the passive avoidance 
test (Douma et al, 2011). Even though it was demonstrated that simvastatin induces apoptosis in 
neurons and astrocytes (Marz et al, 2007), the drug, at a dose of 1.5 mg/kg, did not cause any cell 
loss as observable by the unchanged levels of NeuN, GFAP and of the executive caspase-3, 
excluding that potential neurotoxic effects exerted by simvastatin could be responsible for the 
behavioral outcomes observed in the current study. The lack of toxic effects could be explained by 
the low dose of simvastatin used in the present study. In addition, the safety in terms of necrosis 
and/or apoptosis of this chronic pharmacological treatment was also demonstrated in our previous 
work (Trapani et al, 2011a). The estimation of tissue cholesterol, dolichol and CoQs through HPLC 
analyses also excluded the involvement of these end-products in the onset of the behavioral and 
cognitive changes. The lack of any variation in the amount of these isoprenoids following HMGR 
inhibition is not surprising if it is considered that they possess very long half-lives in the brain 
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(Andersson et al, 1999). Thus, a 3-weeks chronic simvastatin treatment, at the dose used in the our 
study, might not be able to impair the physiological levels of cholesterol, dolichol, CoQ9 and 
CoQ10 in the rat brain areas taken into consideration. On the opposite, membrane-bound Rab3 in 
the synaptic vesicle fraction, which corresponds to the active fraction of the protein, resulted to be 
strongly decreased in both the hippocampus and the prefrontal cortex after chronic HMGR 
inhibition. It is well known that Rab and Rho proteins require prenylation for membrane association 
and for binding to GDIs. GDIs hold prenylated proteins in the cytosol, acting not only as passive 
regulators of GTPase activity, but also preventing their degradation (Boulter and Garcia-Mata, 
2010; Mohamed et al, 2012). GDI capture of membrane-bound Rabs could be physically prevented 
by modifications in cholesterol content within the membranes (Ganley and Pfeffer, 2006). Even 
though the amount of cholesterol into membranes was not evaluated in this work, GDI capture of 
prenylated Rab3 in cytosolic fractions excluded potential interferences of membrane cholesterol in 
RabGDI/Rab3 interaction, suggesting that the deregulation in Rab3 subcellular distribution is due, 
at least in part, to an impairment in Rab3 prenylation induced by HMGR inhibition. Moreover, 
Rab3 seem to be more susceptible to degradational events both in the hippocampus and the 
prefrontal cortex of simvastatin-treated rats. These findings lead us to hypothesize that the lack of 
prenylation could impair Rab3/RabGDI interaction in the cytosol, thus preventing the role of 
RabGDI in protecting Rab proteins from degradation. Although there is a conflicting evidence in 
literature about the modulation of the specific synaptic mechanisms, it is clear and well defined that 
Rab3 carries out important physiological roles in neurotransmitter release at a late step during the 
synaptic vesicle exocytosis (Geppert and Sudhof, 1998). Perturbations in Rab3 activity have already 
been established. For instance, deregulations in Mss4 (mammalian suppressor of Sec4), a regulator 
of Rab3 activity, are strongly linked to impairments in neurotransmitter release and to the 
appearance of neurodegenerative and psychological disorders in rodents such as depressive-like 
syndromes (Andriamampandry et al, 2002; Baskys et al, 2007; Blaveri et al). Given the important 
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role of the hippocampus and the prefrontal cortex in the modulation of anxiety (Whitton and 
Curzon, 1990; Christianson et al, 2009), the decrease in Rab3 active fraction in both the brain 
regions as a molecular consequence of HMGR inhibition, could be related to an impairment in the 
social behavior observed in the social interaction test and could represent a good explanation of the 
MVA pathway-related molecular mechanism underlying the social anxiety-related behavior 
observed in our study.  
Besides the reduction in membrane-bound Rab3 protein levels, the role of MVA pathway in 
emotional memory consolidation could be strongly dependent on the modulation of prenylated 
proteins which are crucial for the induction and the maintenance of LTP. In particular, a strong and 
statistically significant decrease in RhoA active fraction was observed in the amygdala and the 
hippocampus. As for Rab3, additional experiments based on RhoA/RhoGDI interaction further 
support the previous finding, indicating that the reduced amount of RhoA is the consequence of a 
defect in prenylation caused by HMGR pharmacological inhibition. Among Rho GTPases, RhoA 
has been implicated in key neurobiological processes, integrating extracellular and intracellular 
molecular signals to orchestrate refined and coordinated changes in gene expression and actin 
cytoskeleton, essential prerequisites for the neurite outgrowth and the modulation of synaptic 
connectivity (Gopalakrishnan et al, 2008; Lingor et al, 2007). For these reasons, it is not surprising 
that RhoA activity has been deeply related to the onset of developmental disabilities such as mental 
retardation (Ramakers and Storm, 2002). Since RhoA is also considered a negative regulator of Akt, 
whose phosphorylation, and in turn activation, is a key and triggering event for LTP induction and 
consequent memory retention (Ming et al, 2002; Sui et al, 2008), Akt protein levels and 
phosphorylation state were analyzed. In the present work, the reduction in membrane-bound RhoA 
is accompanied by a sustained Akt activation. In order to fully confirm the causality between 
HMGR activity, RhoA activation and Akt phosphorylation, an additional experiment was 
performed on cell culture. To this aim, primary hippocampal neurons were chosen as experimental 
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model in order to avoid the well-known incapability of some used compounds (e.g. mevalonate) to 
cross the blood brain barrier in vivo (Popjak et al, 1977). The rescue experiment performed on 
primary hippocampal neurons demonstrated that the modulation of Akt is strictly dependent on 
RhoA/ROCK pathway, whose activation could be heavily affected by HMGR inhibition. A role of 
Akt in the modulation of cognitive performances in rodents has already been proposed, as it is able 
to induce LTP and other synaptic plasticity phenomena in both the amygdala and the hippocampus 
(Opazo et al, 2003; Sui et al, 2008; Lin et al, 2008). Akt could promote these processes, at least in 
part, by activating the nuclear factor CREB (Du and Montminy, 1998). Indeed, CREB-dependent 
gene transcription appears to be an essential component of long-term memory formation (Silva et 
al, 1998). Our data strengthen this possibility, as Akt activation is followed by an increased CREB 
phosphorylation in simvastatin- and HF-treated hippocampal neurons. The results obtained from 
hippocampal cell cultures are further sustained by p-CREB immunostaining, which is particularly 
positive in the hippocampus of simvastatin-treated rats if compared with vehicle ones. On the 
contrary no differences, in terms of immunoreactivity, were detectable in PSD-95. The obtained 
results are in agreement with other recent published data, which demonstrated that chronic 
simvastatin treatment restores the expression of the learning- and memory-related genes c-Fos and 
Egr-1 without inducing any modulation in the classical synaptic markers synaptophysin and PSD-
95 (Tong et al, 2012). Moreover, considering that c-Fos and Egr-1 are downstream of CREB, our 
findings support the hypothetical model on cognition effects induced by simvastatin proposed by 
Tong and colleagues (2012). However, we cannot exclude that perturbations in cytoskeleton 
remodeling following HMGR inhibition, and in turn RhoA inactivation, could contribute, together 
with Akt induction, to the enhancement of the consolidation of aversive memories. Considering the 
divergences in the brain regional metabolism, it is possible to speculate that each brain area can be 
considered as a unique structure with a specific cellular context, able to react in a different manner 
to the same stimulus (Segatto et al., 2013). Also in this case, despite the generalized influence on 
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mevalonate pathway in the CNS, it is clear that simvastatin treatment selectively affected prenylated 
proteins in specific brain regions. Different effects of HMGR inhibition in dependence on the brain 
area taken into consideration have already been reported (Wang et al, 2006). Thus, the selective 
effects of simvastatin treatment in reducing the amount of Rab3 and RhoA active fractions observed 
in this study could be influenced by differences in metabolism, function, turnover or relative 
abundance of specific prenylated proteins in each brain region. 
Despite the involvement of Rab3 and RhoA, other cellular mechanisms not evaluated in this work 
could contribute to the behavioral and cognitive outcomes induced by simvastatin. Growing 
evidence supports the hypothesis that statins could lead to brain effects, acting through pleiotropic 
mechanisms (Sierra et al, 2011). For instance, previous works identified changes in plasma 
cholesterol with the onset of mood/anxiety disorders and the modulation of memory performance 
(Peter et al, 2002; Henderson et al, 2003; Granholm et al, 2008). Even though the biological 
significance of these connections is not widely accepted and remains to be clarified because of the 
presence of contradictory data (Papakostas et al, 2004; Taylor et al, 2011 ; Reitz et al, 2005), we 
cannot exclude that changes in plasma lipids, also observed in our work, could have a role in the 
functional effects exerted by simvastatin administration. Moreover, a very recent paper showed that 
the enhancement of the autophagic flux alleviates memory deficits in a transgenic mouse model of 
AD (Li et al, 2013) . Since statins induce autophagy in different cell types (Wei et al, 2013; Parikh 
et al, 2010), it is possible that a potential modulation of this process could participate, together with 
the alterations highlighted in this work, in the increased memory consolidation observed in 
simvastatin-treated rats. 
In summary, these findings indicate that the modulation of the isoprenoid/cholesterol biosynthetic 
pathway is critically involved in the physiological modulation of both emotional and cognitive 
processes in rodents (Figure S5). Even though our results provide some hints for the mechanisms of 
action of statins in the CNS, more efforts should be done in order to better understand their 
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pleiotropic molecular effects in the CNS. Thus, the present work sets the stage for a future deeper 
understanding of the effects induced by simvastatin, which could be useful to better define the 
emerging and tight connection between MVA pathway and brain physiopathology. 
 
 
  Supplementary information is available at the Neuropsychopharmacology website. 
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Table 1. Effect of simvastatin on lipid composition of selected brain regions. Number of rats 
contributing to each value are shown in brackets. 
 Cholesterol   
(mg/g tissue) 
Dolichol      
(µg/g tissue) 
CoQ9         
(µg/g tissue) 
CoQ10        
(µg/g tissue)    
 
Amygdala      31.77 ± 9.36 1.37 ± 0.16 3.13 ± 0.36 1.72 ± 0.16 Veh (4)30.45 ± 9.81 1.55 ± 0.17 3.28 ± 0.70 1.75 ± 0.33 Sim (4)
Hippocampus  32.05 ± 6.47 1.47 ± 0.29 3.39 ± 0.07 1.77 ± 0.08 Veh (5)34.15 ± 10.65 1.46 ± 0.13 3.40 ± 0.19 1.91 ± 0.07 Sim (5)
Prefrontal 
cortex  
29.47 ± 9.82 1.35 ± 0.18 3.11 ± 0.29 1.56 ± 0.14 Veh (5)
31.76 ± 5.18 1.46 ± 0.17 3.48 ± 0.17 1.75 ± 0.08 Sim (5)
Dorsal 
striatum  
34.49 ± 2.16 1.48 ± 0.05 3.58 ± 0.32 1.64 ± 0.17 Veh (5)
31.81 ± 2.83 1.46 ± 0.13 4.23 ± 0.24 1.85 ± 0.11 Sim (5)
Ventral 
striatum  
27.42 ± 1.93 1.32 ± 0.06 2.80 ± 0.70 1.26 ± 0.32 Veh (4)
28.36 ± 5.06 1.46 ± 0.25 3.05 ± 0.76 1.38 ± 0.36 Sim (4)
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 Figure legends 
Figure 1. Effects of chronic simvastatin treatment in the social interaction, elevated plus maze 
and inhibitory avoidance tests.  
Simvastatin treatment (1.5 mg/kg per day; i.p.) reduced the total time spent in active social 
interaction (a). No statistically significant difference was found in b) the percentage of time spent in 
the open arms, c) the percentage of open entries and in d) the total arm entries evaluated in the 
elevated plus maze test. Simvastatin treatment e) had no effects on the approach latency in the 
acquisition trial of the inhibitory avoidance task, whereas f) enhanced twenty-four-hour avoidance 
latencies in the retention trial. g) No statistically significance difference was found between 
simvastatin-treated rats and their controls in response to shock delivered during the acquisition trial 
of the inhibitory avoidance test. Data represent mean values ± SEM. *p < 0.05, ***p < 0.001 vs. 
control (n = 10-11 per treatment group). Veh = vehicle-treated rats. Sim = simvastatin-treated rats. 
 
Figure 2. Efficacy of HMGR inhibition by simvastatin and effects on neuronal and astrocytic 
content in different brain regions.  
a) Representative Western blot and densitometric analysis of nSREBP-2 in amygdala (Am), 
hippocampus (Hp), prefrontal cortex, dorsal striatum and ventral striatum. b) Representative 
Western blot and densitometric analysis of LDLr in amygdala (Am), hippocampus (Hp), prefrontal 
cortex, dorsal striatum and ventral striatum. c) Representative Western blot and densitometric 
analysis of the neuronal marker NeuN in amygdala (Am), hippocampus (Hp), prefrontal cortex, 
dorsal striatum and ventral striatum. d) Representative Western blot and densitometric analysis of 
the astrocytic marker GFAP in amygdala (Am), hippocampus (Hp), prefrontal cortex, dorsal 
striatum and ventral striatum. Protein levels were normalized with  α-tubulin. The data are 
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expressed as arbitrary units obtained by analyzing the protein bands with ImageJ software for 
Windows, for details see the main text. All the results obtained are presented as the mean ± S.D. *p 
< 0.05, **p < 0.01; Student’s t test with respect to the control group of the same brain region 
analyzed. n = 6 animals/group. Veh = vehicle-treated rats. Sim = simvastatin-treated rats. 
 
Figure 3. Effect of HMGR inhibition on Rab3 membrane localization and degradation in 
different brain regions. 
a) Representative Western blot and densitometric analysis of Rab3 in preparations of synaptic 
vesicle membranes from amygdala (Am), hippocampus (Hp), prefrontal cortex, dorsal striatum and 
ventral striatum. Rab3 active fraction was expressed as the membrane:cytosol ratio.  
Data are represented as arbitrary units obtained by analyzing the protein bands with ImageJ 
software for Windows, for details see the main text. All the results are expressed as the mean ± S.D. 
*p < 0.05 and **p < 0.01; Student’s t test with respect to the control group of the same brain region 
analyzed. n = 6 animals/group. Veh = vehicle-treated rats. Sim = simvastatin-treated rats. 
b) Representative Western blot obtained by Rab3 degradation assay in cytosolic fractions from 
amygdala, hippocampus, prefrontal cortex, dorsal striatum and ventral striatum. The time course 
analysis was performed at 0, 1, 2, 4, 8, 16 and 24 hours. The results are represented as arbitrary 
units obtained by evaluating the protein bands with ImageJ software for Windows, for details see 
the main text. n = 6 animals/group. Veh = vehicle-treated rats. Sim = simvastatin-treated rats. 
 
Figure 4. Effect of HMGR inhibition by simvastatin on Ras, RhoA membrane localization and 
Akt activation in different brain regions. 
a) Representative Western blot and densitometric analysis of Ras in amygdala (Am), hippocampus 
(Hp), prefrontal cortex, dorsal striatum and ventral striatum. Ras active fraction was expressed as 
the membrane:cytosol ratio. b) Representative Western blot and densitometric analysis of RhoA in 
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amygdala (Am), hippocampus (Hp), prefrontal cortex, dorsal striatum and ventral striatum. RhoA 
active fraction was expressed as the membrane:cytosol ratio. c) Representative Western blot and 
densitometric analysis of Akt phosphorylation/activation in amygdala (Am), hippocampus (Hp), 
prefrontal cortex, dorsal striatum and ventral striatum. Protein levels were normalized with α-
tubulin. The results are represented as arbitrary units obtained by analyzing the protein bands with 
ImageJ software for Windows, for details see the main text. All the data are expressed as the mean 
± S.D. *p < 0.05; Student’s t test with respect to the control group of the same brain region 
analyzed. n = 6 animals/group. Veh = vehicle-treated rats. Sim = simvastatin-treated rats. 
 
Figure 5. Akt phosphorylation and the consequent CREB activation are dependent on 
RhoA/ROCK pathway. 
a) Representative Western blot and densitometric analysis of RhoA in primary hippocampal 
neurons. RhoA active fraction was expressed as the membrane:cytosol ratio. All the data are 
expressed as arbitrary units obtained by analyzing the protein bands with ImageJ software for 
Windows, for details see the main text. b) Representative Western blot and densitometric analysis 
of Akt phosphorylation/activation in primary hippocampal neurons. p-Akt protein levels were 
normalized with total Akt levels and α-tubulin. c) Representative Western blot and densitometric 
analysis of CREB phosphorylation/activation in primary hippocampal neurons. p-CREB protein 
levels were normalized with total CREB levels and α-tubulin. All the data are expressed as arbitrary 
units obtained by evaluating the protein bands with ImageJ software for Windows, for details see 
the main text. All the results represent the mean ± S.D of at least three different experiments. *p < 
0.05, **p < 0.01, and ***p < 0.001determined using one-way ANOVA followed by Dunnett post-
test. Veh = vehicle; Sim = simvastatin; MVA = mevalonate; GG = geranylgeraniol; HF = 
hydroxyfasudil. 
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Figure 6. p-CREB and PSD-95 distribution in hippocampus of simvastatin- and vehicle-
treated rats. 
(a) Overview of p-CREB immunohistochemistry in a sagittal section of rat brain. Hippocampal 
formation  showed higher positivity in the nucleus of pyramidal cells in CA1-CA3 fields and of 
granule cells in DG. Mossy cells in the hylus were especially immunoreactive. 
b) Overview of PSD-95 immunohistochemistry in a sagittal section of rat brain showing 
immunopositivity localized to pyramidal cell layer of CA1-CA3, to granule neurons of DG, and to 
hylar mossy neurons. 
Hp, hippocampus; Or, stratum oriens; Pyr, stratum pyramidale; Rad, stratum radiatum; GL, granule 
cell layer; PoDG, polymorphic layer; ML, molecular layer. 
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